ESLA (Estrella Immunopharma) Change In Payables And Accrued Expense : $4.14 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Change In Payables And Accrued Expense?

Estrella Immunopharma's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $1.28 Mil. It means Estrella Immunopharma's Accounts Payable & Accrued Expense increased by $1.28 Mil from Dec. 2024 to Mar. 2025 .

Estrella Immunopharma's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was $8.54 Mil. It means Estrella Immunopharma's Accounts Payable & Accrued Expense increased by $8.54 Mil from Jun. 2022 to Jun. 2023 .

Estrella Immunopharma Change In Payables And Accrued Expense Historical Data

The historical data trend for Estrella Immunopharma's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Change In Payables And Accrued Expense Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Jun22

Jun23

Change In Payables And Accrued Expense

0.95

8.54

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial										-0.26	0.04	2.81	0.01	1.28

Estrella Immunopharma Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.14 Mil.

Estrella Immunopharma Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.